BackCanopus Biopharma Overview

Canopus Biopharma Current Assets

Track Canopus Biopharma's current assets ($6.2K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$6153.00
↓ 21.98% YoYΔ $-1733.00 vs prior year quarter

Peer trimmed avg / median

Loading

Canopus Biopharma Current Assets History

Loading

Canopus Biopharma vs. peers: Current Assets Comparison

Loading

Canopus Biopharma Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Canopus Biopharma (CBIA) FAQ

Canopus Biopharma (CBIA) currently reports a current assets of $6.2K as of May 2023. That compares with $7.9K in the prior-year period — down 22.0% year over year. Use the charts on this page to explore Canopus Biopharma's current assets history and peer comparisons.

Canopus Biopharma's current assets decreased from $7.9K to $6.2K — a 22.0% year-over-year decrease (period ending May 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Canopus Biopharma reported $6.2K in current assets as of May 2023. That compares with $7.9K in the prior-year period — down 22.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $6.2K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Canopus Biopharma, and consider following CBIA for alerts when major investors trade the stock.